We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection (LATHCV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01182298
Recruitment Status : Terminated (small number of patients enrolled)
First Posted : August 16, 2010
Results First Posted : October 2, 2014
Last Update Posted : October 2, 2014
Fundación de Investigación de Diego
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )

Study Type: Observational
Study Design: Observational Model: Cohort;   Time Perspective: Prospective
Conditions: Hepatitis C

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
PegIFN and Ribavirin

Latino Patients with hepatitis C receiving weekly pegIFN and ribavirin.

This is an observational study. The observed treatment is received and managed through their primary care.

Participant Flow:   Overall Study
    PegIFN and Ribavirin
Lack of Efficacy                4 
Withdrawal by Subject                2 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

Reporting Groups

Baseline Measures
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
<=18 years   0 
Between 18 and 65 years   10 
>=65 years   0 
[Units: Participants]
Female   3 
Male   7 
Ethnicity (NIH/OMB) 
[Units: Participants]
Hispanic or Latino   10 
Not Hispanic or Latino   0 
Unknown or Not Reported   0 
Region of Enrollment 
[Units: Participants]
United States   0 
Puerto Rico   10 

  Outcome Measures

1.  Primary:   Median Log Change in HCV RNA Levels on Day 7   [ Time Frame: first 7 days ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Early termination due to small numbers of subjects enrolled as the options for HCV treatment changed significantly since the start of the study planning.

  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Shyam Kottilil
Organization: NIAID
e-mail: Skottilil@niaid.nih.gov


Responsible Party: National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )
ClinicalTrials.gov Identifier: NCT01182298     History of Changes
Other Study ID Numbers: 100159
10-I-0159 ( Registry Identifier: CLINICAL TRIALS )
First Submitted: August 13, 2010
First Posted: August 16, 2010
Results First Submitted: April 23, 2014
Results First Posted: October 2, 2014
Last Update Posted: October 2, 2014